GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » EPS (Diluted)

Lucy Scientific Discovery (Lucy Scientific Discovery) EPS (Diluted) : $-7.08 (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery EPS (Diluted)?

Lucy Scientific Discovery's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.48. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.08.

Lucy Scientific Discovery's EPS (Basic) for the three months ended in Dec. 2023 was $-1.40. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.00.

Lucy Scientific Discovery's EPS without NRI for the three months ended in Dec. 2023 was $-0.74. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.37.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Lucy Scientific Discovery EPS (Diluted) Historical Data

The historical data trend for Lucy Scientific Discovery's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery EPS (Diluted) Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
EPS (Diluted)
-2.90 -3.60 -7.10

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.61 -3.00 -1.50 -1.10 -1.48

Competitive Comparison of Lucy Scientific Discovery's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucy Scientific Discovery's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's PE Ratio falls into.



Lucy Scientific Discovery EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Lucy Scientific Discovery's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.988-0)/1.270
=-7.08

Lucy Scientific Discovery's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.62-0)/1.765
=-1.48

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucy Scientific Discovery  (NAS:LSDI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lucy Scientific Discovery EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Traded in Other Exchanges
N/A
Address
301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.
Executives
Richard D Nanula director, officer: Executive Chairman C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko officer: Chief Financial Officer C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany director, officer: President and CEO C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy officer: Chief Scientific Officer C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6